2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1939

Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Abstract Number: 3045

Immunometabolism in ANCA-Associated Glomerulonephritis
Abstract Number: 2109

Immunoprofiling of Bruton’s Tyrosine Kinase (Btk)/Tec Family Kinase Inhibitors Indicate Activities Beyond Btk in Immunocyte Function
Abstract Number: 3200

Immunoscintigraphic Detection Of Tumor Necrosis Factor By Radiolabeled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis in Relation to Disease Activity: A Proof of Concept Study
Abstract Number: 1892

Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement
Abstract Number: 839

Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Abstract Number: 831

Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 3059

Impact of a Musculoskeletal Training Program on Residents’ Evaluation, Diagnosis, and Treatment of Osteoporosis
Abstract Number: 80

Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Abstract Number: 1142

Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology
Abstract Number: 592

Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Abstract Number: 722

Impact of Aerobic Fitness on Axial Spondyloarthritis Activity: Systematic Review and Meta-Analysis of Controlled Studies
Abstract Number: 231

Impact of an Educational Program for the Management of Gout Directed to Primary Care Physicians
Abstract Number: 496

Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Abstract Number: 2172

Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].